SGMO: Discontinuing Research Coverage

研报英文原文证据摘录

SGMO: Discontinuing Research Coverage

d to full approval.

All values in USD unless otherwise noted.RESEARCH Priced as of prior trading day's market close, EST (unless otherwise noted). Neuro Epigenetic Regulation Pipeline Advancing into the Clinic. SGMO is

advancing its neurology franchise with sites activated for the Phase 1/2

STAND study evaluating ST-503 (Nav1.7 epigenetic regulator) for chronic

neuropathic pain, and CTA-enabling activities underway for ST-506 in

prion disease, leveraging the proprietary STAC-BBB neurotropic AAV capsid.

Preclinical data for the neuro programs have demonstrated durable target

engagement, favorable safety profiles, and survival extension in disease

mouse models and widespread brain delivery in NHPs.EQUITY

SGMO Eligible for Milestone Payments Across Partnerships. STAC-BBB

has been licensed to Genentech, Astellas, and Eli Lilly and SGMO remains

eligible for up to $4.6b in potential future milestones and exercise fees

(assuming exercise of all options and targets), plus royalties on approved

product sales across all five potential neurology disease targets.

Platform Differentiated from CRISPR/Cas9. SGMO has pioneered the

field of zinc finger proteins (ZFPs), highly selective DNA binding proteins.

Importantly, ZFP are modular tools that can be used for gene editing or to

modulate transcription. We see a few differences vs. CRISPR: 1) small size,

so amenable to AAV (Cas9 is too big); 2) the platform has higher barriers

to entry given that selectivity requires engineering the aa sequence; and

3) ZFPs are human proteins (not bacteria like CRISPR) and therefore have

lower immunogenicity risk.

Disseminated: Jun 18, 2026 16:05EDT; Produced: Jun 18, 2026 15:56EDT

For Required Conflicts Disclosures, see page 2